Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of BCMA CAR-T in Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03559764
Recruitment Status : Unknown
Verified June 2018 by Allife Medical Science and Technology Co., Ltd..
Recruitment status was:  Not yet recruiting
First Posted : June 18, 2018
Last Update Posted : June 18, 2018
Information provided by (Responsible Party):
Allife Medical Science and Technology Co., Ltd.

Brief Summary:
This is a single centre、single arm、open-label,to investigate the safety and efficacy of anti-BCMA CAR T cells in patients with Relapsed and Refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Relapsed and Refractory Multiple Myeloma Biological: Anti-BCMA CAR T cells Early Phase 1

Detailed Description:

Multiple myeloma(MM) is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways.CAR - T cells was taken in the form of genetic modification, and specific identified target antigen monoclonal antibody of single variable region (scFv) expression in T cell surface, and coupled with the activation of intracellular proliferation signal domain. The study will follow a 3 + 3 design of dose-escalating cohorts. After a patient enrolls,leukapheresis will be performed to obtain peripheral blood mononuclear cells which will be sent to a manufacturing site to produce anti- BCMA CAR T cells. The cells will then be returned to the investigational site and, after a standard chemotherapy based conditioning regimen, will be administered to the patient. Treated patients will undergo serial measurements of safety, tolerability and response.

In order to lay a foundation for the application of relapsed/refractory multiple myeloma patients with CAR-T therapy,objects are refractory/ relapsed patients with multiple myeloma,and plans to into the group of the number of cases in 20 cases.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study on the Safety and Efficacy of Anti-BCMA CAR T Cells With Relapsed and Refractory Multiple Myeloma
Estimated Study Start Date : June 2018
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : May 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Anti-BCMA CAR T cells
Total dose of 0.5-6 millions /kg cells will be administered at day -2, day -1 and day 0 by split dose (30%, 30% and 40% respectively).
Biological: Anti-BCMA CAR T cells
Transparent colorless or slightly yellow liquid

Primary Outcome Measures :
  1. The safety of CAR T is evaluated to determine if CRS occurred [ Time Frame: Day 3-Year 2 after injection ]
    defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, 18 to 70 years old (including 18 and 70 years old)
  2. BCMA antigen diagnosed by pathology and histological examination was positive
  3. ECOG ≤2,and the excepted survival ≥ 3 months
  4. Patients with BCMA+ myeloma who received ≥ 1 line of chemoradiotherapy or tumor relapsed
  5. The main organs function is good; (1) liver function: ALT/AST<3 times normal value upper limit (ULN) and total bilirubin <34.2 (mol/L); (2) renal function: creatinine <220 mu /L,GFR > 30mL/min; (3) lung function: blood oxygen saturation is greater than 95%; (4) cardiac function: left ventricular ejection fraction (LVEF) is greater than 50%;
  6. Platelets > 40 billion/L;
  7. Patients without any anti-cancer treatment such as chemotherapy,radiotherapy, immunotherapy( immunosuppressive drugs )within 2-4 weeks before, and the treatment-related toxicity reaction ≤1 level prior to enrollment(except low toxicity lose hair for example)
  8. Venous channel is unobstructed, which can meet the needs of intravenous drip;
  9. Voluntary informed consent is given, agree to follow the trial treatment and visit plan.

Exclusion Criteria:

  1. Patients with allergy to large molecules such as antibodies or cytokines;
  2. More than 5mg of hormones (except patients with inhaled hormone) were used within 2 to 4 weeks prior enrollment;
  3. Patients with severe autoimmune diseases or immunodeficiency diseases;
  4. Patients treated with other immune cellular products (DC, CIK, T, NK, and CART products with CD19 or other targets);
  5. Patients with uncontrollable infectious disease in the first 4 weeks of treatment;
  6. Active hepatitis B DNA > 1000copy/mL/ , hepatitis C positive, (HCV positive resistance, HCV RNA positive);
  7. Patients participated in other clinical trials within 6 weeks prior enrollment;
  8. Patients with mental illness;
  9. Patients with drug abuse/addiction and medical, psychological or social conditions may interfere with the study or evaluate the results of the study;
  10. Patients have alcohol dependence;
  11. Pregnant or lactating women; Men or women who have a pregnancy plan within a year; The patients cannot guarantee effective contraceptive measures during the trial period;
  12. Patients had other conditions that were not appropriate for the group determined by the researchers.
Layout table for additonal information
Responsible Party: Allife Medical Science and Technology Co., Ltd. Identifier: NCT03559764    
Other Study ID Numbers: BCMA CAR T-HNRM-01
First Posted: June 18, 2018    Key Record Dates
Last Update Posted: June 18, 2018
Last Verified: June 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases